IDEXX Laboratories vs Baxter International: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

IDEXX Laboratories Inc (IDXX)

Q3 202621 Jul – 20 Sep 2026

▲4

IDEXX beats Q2, raises 2026 outlook, buys AI vet software

Q2 beat and raised 2026 guidance IDEXX's second-quarter revenue rose about 10% and earnings per share 18%, beating expectations, and management raised full-year EPS guidance to $14.69-$14.94. Strong recurring diagnostics demand and wider margins (35% operating) tell investors the core business is growing faster than expected, lifting the stock.
The quarter's results and guidance raise are the main new force behind IDXX's price this period.
Acquires CoVetAI to add AI scribe software IDEXX bought CoVetAI, which makes AI listening and workflow software that cuts veterinarians' paperwork. It plugs into IDEXX's software ecosystem and works with rival systems too, deepening the company's software and AI offerings and making its diagnostic tools stickier with clinics.
A new acquisition that expands IDEXX's software and AI capabilities, a fresh driver of future growth.
Reaffirms long-term growth and pipeline progress At a healthcare conference IDEXX repeated targets of over 10% organic revenue and over 15% EPS growth, with a 32%-plus operating margin. Its inVue Dx cytology tool is already hitting per-instrument revenue goals, Cancer Dx is widening to more cancers, and a new heart test launches in October.
Management's reaffirmed targets and pipeline updates give investors confidence in durable growth.
New UK tapeworm test broadens diagnostics menu IDEXX expanded its Faecal Dx antigen platform in the UK to detect taeniid tapeworm at no extra cost, now covering seven parasite groups. It strengthens the reference-lab offering and gives clinics more reasons to send tests to IDEXX, supporting recurring revenue.
A concrete product expansion that supports IDEXX's diagnostics demand and pricing power.

August 202621 Jul – 20 Sep 2026

▲4

IDEXX beats Q2, raises 2026 outlook, buys AI vet software

Q2 beat and raised 2026 guidance IDEXX's second-quarter revenue rose about 10% and earnings per share 18%, beating expectations, and management raised full-year EPS guidance to $14.69-$14.94. Strong recurring diagnostics demand and wider margins (35% operating) tell investors the core business is growing faster than expected, lifting the stock.
The quarter's results and guidance raise are the main new force behind IDXX's price this period.
Acquires CoVetAI to add AI scribe software IDEXX bought CoVetAI, which makes AI listening and workflow software that cuts veterinarians' paperwork. It plugs into IDEXX's software ecosystem and works with rival systems too, deepening the company's software and AI offerings and making its diagnostic tools stickier with clinics.
A new acquisition that expands IDEXX's software and AI capabilities, a fresh driver of future growth.
Reaffirms long-term growth and pipeline progress At a healthcare conference IDEXX repeated targets of over 10% organic revenue and over 15% EPS growth, with a 32%-plus operating margin. Its inVue Dx cytology tool is already hitting per-instrument revenue goals, Cancer Dx is widening to more cancers, and a new heart test launches in October.
Management's reaffirmed targets and pipeline updates give investors confidence in durable growth.
New UK tapeworm test broadens diagnostics menu IDEXX expanded its Faecal Dx antigen platform in the UK to detect taeniid tapeworm at no extra cost, now covering seven parasite groups. It strengthens the reference-lab offering and gives clinics more reasons to send tests to IDEXX, supporting recurring revenue.
A concrete product expansion that supports IDEXX's diagnostics demand and pricing power.

Latest21 Jul – 20 Sep 2026

▲4

IDEXX beats Q2, raises 2026 outlook, buys AI vet software

Q2 beat and raised 2026 guidance IDEXX's second-quarter revenue rose about 10% and earnings per share 18%, beating expectations, and management raised full-year EPS guidance to $14.69-$14.94. Strong recurring diagnostics demand and wider margins (35% operating) tell investors the core business is growing faster than expected, lifting the stock.
The quarter's results and guidance raise are the main new force behind IDXX's price this period.
Acquires CoVetAI to add AI scribe software IDEXX bought CoVetAI, which makes AI listening and workflow software that cuts veterinarians' paperwork. It plugs into IDEXX's software ecosystem and works with rival systems too, deepening the company's software and AI offerings and making its diagnostic tools stickier with clinics.
A new acquisition that expands IDEXX's software and AI capabilities, a fresh driver of future growth.
Reaffirms long-term growth and pipeline progress At a healthcare conference IDEXX repeated targets of over 10% organic revenue and over 15% EPS growth, with a 32%-plus operating margin. Its inVue Dx cytology tool is already hitting per-instrument revenue goals, Cancer Dx is widening to more cancers, and a new heart test launches in October.
Management's reaffirmed targets and pipeline updates give investors confidence in durable growth.
New UK tapeworm test broadens diagnostics menu IDEXX expanded its Faecal Dx antigen platform in the UK to detect taeniid tapeworm at no extra cost, now covering seven parasite groups. It strengthens the reference-lab offering and gives clinics more reasons to send tests to IDEXX, supporting recurring revenue.
A concrete product expansion that supports IDEXX's diagnostics demand and pricing power.

Baxter International Inc (BAX)

Q3 202629 Jul – 7 Sep 2026

▲2▼2

Baxter's Q2 beat and raised 2026 outlook lift shares, but margins stay squeezed

Q2 beat and raised guidance Baxter's second-quarter sales rose 5% to $2.96 billion and adjusted profit hit 56 cents a share, far above the 37 cents analysts expected. Management raised full-year sales and earnings guidance, a sign the core business is steadier than feared. The stock jumped sharply on the news.
This is the main new event that moved BAX and reset expectations for the year.
Debt buyback upsized Baxter increased its cash tender offer cap to $600 million, buying back several older bonds. Paying down or refinancing debt can lower interest costs and steady the balance sheet, which supports the stock by reducing financial risk.
It is a new capital-structure action that affects how investors view BAX's debt load.
Margins still under pressure Even with the upbeat quarter, adjusted gross margin fell to 38.6% and operating margin slipped to 14.2%, hurt by costly inventory, manufacturing expenses and tariffs. That means profit per sale is still shrinking, a real counterweight to the good headline numbers.
It is the main negative in the new results and explains why the beat is not purely good news.
Infusion pump hold drags on Baxter's Novum IQ large-volume pump remains under a shipment and installation hold, with customer returns and a shift to older Spectrum pumps. That is holding back Infusion Systems sales and is an execution risk that could keep a lid on growth until resolved.
It is a specific new operational risk flagged alongside the raised outlook.

August 202629 Jul – 7 Sep 2026

▲2▼2

Baxter's Q2 beat and raised 2026 outlook lift shares, but margins stay squeezed

Q2 beat and raised guidance Baxter's second-quarter sales rose 5% to $2.96 billion and adjusted profit hit 56 cents a share, far above the 37 cents analysts expected. Management raised full-year sales and earnings guidance, a sign the core business is steadier than feared. The stock jumped sharply on the news.
This is the main new event that moved BAX and reset expectations for the year.
Debt buyback upsized Baxter increased its cash tender offer cap to $600 million, buying back several older bonds. Paying down or refinancing debt can lower interest costs and steady the balance sheet, which supports the stock by reducing financial risk.
It is a new capital-structure action that affects how investors view BAX's debt load.
Margins still under pressure Even with the upbeat quarter, adjusted gross margin fell to 38.6% and operating margin slipped to 14.2%, hurt by costly inventory, manufacturing expenses and tariffs. That means profit per sale is still shrinking, a real counterweight to the good headline numbers.
It is the main negative in the new results and explains why the beat is not purely good news.
Infusion pump hold drags on Baxter's Novum IQ large-volume pump remains under a shipment and installation hold, with customer returns and a shift to older Spectrum pumps. That is holding back Infusion Systems sales and is an execution risk that could keep a lid on growth until resolved.
It is a specific new operational risk flagged alongside the raised outlook.

Latest29 Jul – 7 Sep 2026

▲2▼2

Baxter's Q2 beat and raised 2026 outlook lift shares, but margins stay squeezed

Q2 beat and raised guidance Baxter's second-quarter sales rose 5% to $2.96 billion and adjusted profit hit 56 cents a share, far above the 37 cents analysts expected. Management raised full-year sales and earnings guidance, a sign the core business is steadier than feared. The stock jumped sharply on the news.
This is the main new event that moved BAX and reset expectations for the year.
Debt buyback upsized Baxter increased its cash tender offer cap to $600 million, buying back several older bonds. Paying down or refinancing debt can lower interest costs and steady the balance sheet, which supports the stock by reducing financial risk.
It is a new capital-structure action that affects how investors view BAX's debt load.
Margins still under pressure Even with the upbeat quarter, adjusted gross margin fell to 38.6% and operating margin slipped to 14.2%, hurt by costly inventory, manufacturing expenses and tariffs. That means profit per sale is still shrinking, a real counterweight to the good headline numbers.
It is the main negative in the new results and explains why the beat is not purely good news.
Infusion pump hold drags on Baxter's Novum IQ large-volume pump remains under a shipment and installation hold, with customer returns and a shift to older Spectrum pumps. That is holding back Infusion Systems sales and is an execution risk that could keep a lid on growth until resolved.
It is a specific new operational risk flagged alongside the raised outlook.